Neoadjuvant immunotherapy in resectable non-small-cell lung cancer
The advent of immune checkpoint inhibition has pushed the treatment paradigm for resectable non-small-cell lung cancer (NSCLC) toward neoadjuvant therapy. A growing number of promising trials have examined the utility of neoadjuvant immunotherapy, both alone and in combination with other modalities...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-03-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359231163798 |